Pancreatic Neuroendocrine Tumors Pnet Market Size

DelveInsight's 'Pancreatic Neuroendocrine Tumors (PNET) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of PNET in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Pancreatic Neuroendocrine Tumors (PNET) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan


Study Period: 2017-2028


Pancreatic Neuroendocrine Tumors (PNET) - Disease Understanding and Treatment Algorithm

The DelveInsight Pancreatic Neuroendocrine Tumors (PNET) market report gives the thorough understanding of the Pancreatic Neuroendocrine Tumors by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Pancreatic Neuroendocrine Tumors in the US, Europe, and Japan.

Pancreatic Neuroendocrine Tumors Epidemiology

The Pancreatic Neuroendocrine Tumors (PNET) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, functionality based prevalent cases, stage-wise prevalent cases, grade-wise prevalent cases and prevalent cases based on gender) scenario of Pancreatic Neuroendocrine Tumors (PNET) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of prevalent cases of Pancreatic Neuroendocrine Tumors (PNET) in 7 MM was found to be 8,470, in the year 2017.


Pancreatic Neuroendocrine Tumors Drug Chapters

This segment of the Pancreatic Neuroendocrine Tumors report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The market forecast solely focuses on the market revenue generated by the pharmacological treatment (inclusive of LUTATHERA, Afinitor, Somaline, and SUTENT) used for the management of PNET. The initial three therapies have been granted orphan drug designation for the treatment of PNET. Detailed chapter for upcoming therapies like Surufatinib (Hutchison Medipharma Limited) and CVM-1118 (TaiRx, Inc.) have been covered in the report.


Pancreatic Neuroendocrine Tumors Market Outlook

The Pancreatic Neuroendocrine Tumors market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Pancreatic Neuroendocrine Tumors in 7MM was found to be USD 351.7 million in 2017, and is expected to increase at a CAGR of XX% from 2017-2028.


Pancreatic Neuroendocrine Tumors Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pancreatic Neuroendocrine Tumors Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Pancreatic Neuroendocrine Tumors Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition

Pancreatic Neuroendocrine Tumors Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers


Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Pancreatic Neuroendocrine Tumors market

• Organize sales and marketing efforts by identifying the best opportunities for Pancreatic Neuroendocrine Tumors market

• To understand the future market competition in the Pancreatic Neuroendocrine Tumors market.

1. Key Insights

2. Pancreatic Neuroendocrine Tumors Market Overview at a Glance

2.1. Market Share (%) Distribution of Pancreatic Neuroendocrine Tumors (PNET) in 2017

2.2. Market Share (%) Distribution of Pancreatic Neuroendocrine Tumors (PNET) in 2028

3. Disease Background and Overview: Pancreatic Neuroendocrine Tumors (PNET)

3.1. Introduction

3.2. Signs and Symptoms

3.3. Staging of Pancreatic Neuroendocrine Tumors (PNET)

3.4. Etiology and Risk Factors

3.5. Pathophysiology

3.6. Biomarkers

3.7. Diagnosis

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. Total Prevalent Cases of PNET in 7MM countries

5. Country Wise-Epidemiology of PNET

5.1. The United States

5.1.1. Prevalence of PNET in the United States

5.1.2. Functionality based Prevalence of PNET in the United States

5.1.3. Stage-wise Prevalence of PNET in the United States

5.1.4. Grade-wise Prevalence of PNET in the United States

5.1.5. Gender-specific Prevalence of PNET in the United States

5.2. EU5 Countries

5.3. Germany

5.3.1. Prevalence of PNET in Germany

5.3.2. Functionality based Prevalence of PNET in Germany

5.3.3. Stage-wise Prevalence of PNET in Germany

5.3.4. Grade-wise Prevalence of PNET in Germany

5.3.5. Gender-specific Prevalence of PNET in Germany

5.4. France

5.4.1. Prevalence of PNET in France

5.4.2. Functionality based Prevalence of PNET in France

5.4.3. Stage-wise Prevalence of PNET in France

5.4.4. Grade-wise Prevalence of PNET in France

5.4.5. Gender-specific Prevalence of PNET in France

5.5. Italy

5.5.1. Prevalence of PNET in Italy

5.5.2. Functionality based Prevalence of PNET in Italy

5.5.3. Stage-wise Prevalence of PNET in Italy

5.5.4. Grade-wise Prevalence of PNET in Italy

5.5.5. Gender-specific Prevalence of PNET in Italy

5.6. Spain

5.6.1. Prevalence of PNET in Spain

5.6.2. Functionality based Prevalence of PNET in Spain

5.6.3. Stage-wise Prevalence of PNET in Spain

5.6.4. Grade-wise Prevalence of PNET in Spain

5.6.5. Gender-specific Prevalence of PNET in Spain

5.7. United Kingdom

5.7.1. Prevalence of PNET in the UK

5.7.2. Functionality based Prevalence of PNET in the UK

5.7.3. Stage-wise Prevalence of PNET in the UK

5.7.4. Grade-wise Prevalence of PNET in the UK

5.7.5. Gender-specific Prevalence of PNET in The UK

5.8. Japan

5.9. Prevalence of PNET in Japan

5.10. Functionality based Prevalence of PNET in Japan

5.11. Stage-wise Prevalence of PNET in Japan

5.12. Grade-wise Prevalence of PNET in Japan

5.13. Gender-specific Prevalence of PNET in Japan

6. Treatment Practices

6.1. Treatment Goals

6.2. Treatment Strategy

6.3. Treatment Algorithm based on NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines for Treatment

7. Unmet Needs

8. Marketed Products

8.1. Marketed Drug Analysis

8.2. Lutathera: Advanced Accelerator Applications

8.2.1. Drug Description

8.2.2. Regulatory Milestones

8.2.3. Other Development Activities

8.2.4. Clinical Development

8.2.5. Safety and Efficacy

8.2.6. Product Profile

8.3. Afinitor: Novartis Pharmaceutical

8.3.1. Drug Description

8.3.2. Regulatory Milestones

8.3.3. Other Development Activities

8.3.4. Clinical Development

8.3.5. Safety and Efficacy

8.3.6. Product Profile

8.4. Somatuline Depot: Ipsen Pharma S.A.S.

8.4.1. Drug Description

8.4.2. Regulatory Milestones

8.4.3. Other Development Activities

8.4.4. Clinical Development

8.4.5. Safety and Efficacy

8.4.6. Product Profile

8.4.7. Other Somatostatin Analogues (SSAs)

8.5. Sutent: Pfizer

8.5.1. Drug Description

8.5.2. Regulatory Milestones

8.5.3. Other Development Activities

8.5.4. Clinical Development

8.5.5. Safety and Efficacy

8.5.6. Product Profile

9. Other Promising Candidates

9.1. Surufatinib: Hutchison Medipharma Limited

9.1.1. Product Description

9.1.2. Other development activities

9.1.3. Clinical Development

9.1.4. Safety and Efficacy

9.1.5. Product Profile

9.2. CVM-1118: TaiRx, Inc.

9.2.1. Product Description

9.2.2. Other development activities

9.2.3. Clinical Development

9.2.4. Product Profile

10. Pancreatic Neuroendocrine Tumors [PNET] Market Analysis: 7MM

10.1. Key Findings

10.2. Total Market Size of Pancreatic Neuroendocrine Tumor (PNET) in 7MM

10.3. Market Size of PNET by Therapies in 7MM

11. Market Outlook by Country

11.1. The United States: Market Outlook

11.2. United States Market Size

11.2.1. Total Market size of pNET

11.2.2. PNET Market Size by Therapies

11.3. EU-5 Countries: Market Outlook

11.4. Germany Market Size

11.4.1. Total Market size of PNET

11.4.2. PNET Market Size by Therapies

11.5. France Market Size

11.5.1. Total Market size of pNET

11.5.2. PNET Market Size by Therapies

11.6. Italy Market Size

11.6.1. Total Market size of pNET

11.6.2. PNET Market Size by Therapies

11.7. Spain Market Size

11.7.1. Total Market size of pNET

11.7.2. PNET Market Size by Therapies

11.8. The United Kingdom Market Size

11.8.1. Total Market size of PNET

11.8.2. PNET Market Size by Therapies

11.9. Japan: Market Outlook

11.10. Japan: Market Size

11.10.1. Total Market size of PNET

11.10.2. PNET Market Size by Therapies

12. Market Drivers

13. Market Barriers

14. Appendix

14.1. Report Methodology

15. Sources Used

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

Table 1: Total Prevalent Cases of PNET in 7 MM (2017-2028)

Table 2: Prevalence of PNET in the United States (2017-2028)

Table 3: Functionality based prevalence of PNET in the United States (2017-2028)

Table 4: Symptom based Prevalence of Functional PNET in the United States (2017-2028)

Table 5: Stage-wise prevalence of PNET in the United States (2017-2028)

Table 6: Grade-wise prevalence of PNET in the United States (2017-2028)

Table 7: Gender-specific prevalence of PNET in the United States (2017-2028)

Table 8: Prevalence of PNET in Germany (2017-2028)

Table 9: Functionality based prevalence of PNET in Germany (2017-2028)

Table 10: Symptom based Prevalence of Functional PNET in Germany (2017-2028)

Table 11: Stage-wise prevalence of PNET in Germany (2017-2028)

Table 12: Grade-wise prevalence of PNET in Germany (2017-2028)

Table 13: Gender-specific prevalence of PNET in Germany (2017-2028)

Table 14: Prevalence of PNET in France (2017-2028)

Table 15: Functionality based prevalence of PNET in France (2017-2028)

Table 16: Symptom based Prevalence of Functional PNET in France (2017-2028)

Table 17: Stage-wise prevalence of PNET in France (2017-2028)

Table 18: Grade-wise prevalence of PNET in France (2017-2028)

Table 19: Gender-specific prevalence of PNET in France (2017-2028)

Table 20: Prevalence of PNET in Italy (2017-2028)

Table 21: Functionality based prevalence of PNET in Italy (2017-2028)

Table 22: Symptom based Prevalence of Functional PNET in Italy (2017-2028)

Table 23: Stage-wise prevalence of PNET in Italy (2017-2028)

Table 24: Grade-wise prevalence of PNET in Italy (2017-2028)

Table 25: Gender-specific prevalence of PNET in Italy (2017-2028)

Table 26: Prevalence of PNET in Spain (2017-2028)

Table 27: Functionality based prevalence of PNET in Spain (2017-2028)

Table 28: Symptom based Prevalence of Functional PNET in Spain (2017-2028)

Table 29: Stage-wise prevalence of PNET in Spain (2017-2028)

Table 30: Grade-wise prevalence of PNET in Spain (2017-2028)

Table 31: Gender-specific prevalence of PNET in Spain (2017-2028)

Table 32: Prevalence of PNET in the UK (2017-2028)

Table 33: Functionality based prevalence of PNET in the UK (2017-2028)

Table 34: Symptom based Prevalence of Functional PNET in the UK (2017-2028)

Table 35: Stage-wise prevalence of PNET in the UK (2017-2028)

Table 36: Grade-wise prevalence of PNET in the UK (2017-2028)

Table 37: Gender-specific prevalence of PNET in the UK (2017-2028)

Table 38: Prevalence of PNET in Japan (2017-2028)

Table 39: Functionality based prevalence of PNET in Japan (2017-2028)

Table 40: Symptom based Prevalence of Functional PNET in Japan (2017-2028)

Table 41: Stage-wise prevalence of PNET in Japan (2017-2028)

Table 42: Grade-wise prevalence of PNET in Japan (2017-2028)

Table 43: Gender-specific prevalence of PNET in Japan (2017-2028)

Table 44: CVM-1118 Clinical Trial Description, 2019

Table 45: Market Size of PNET in 7MM, USD Million (2017-2028)

Table 46: PNET Market Size by therapies in 7MM, USD Million (2017-2028)

Table 47: Market Size of PNET in the US, Million (2017-2028)

Table 48: PNET Market Size by Therapies in the US, USD Million (2017-2028)

Table 49: Market Size of PNET in Germany, USD Millions (2017-2028)

Table 50: PNET Market Size by therapies in Germany, USD Million (2017-2028)

Table 51: Market Size of PNET in France, USD Millions (2017-2028)

Table 52: PNET Market Size by therapies in France, USD Million (2017-2028)

Table 53: Market Size of PNET in Italy, USD Millions (2017-2028)

Table 54: PNET Market Size by therapies in Italy, USD Million (2017-2028)

Table 55: Market Size of PNET in Spain, USD Millions (2017-2028)

Table 56: PNET Market Size by therapies in Spain, USD Million (2017-2028)

Table 57: Market Size of PNET in the UK, USD Millions (2017-2028)

Table 58: PNET Market Size by therapies in the UK, USD Million (2017-2028)

Table 59: Market Size of PNET in Japan, USD Millions (2017-2028)

Table 60: PNET Market Size by therapies in Japan, USD Million (2017-2028)

Figure 1: Total Prevalent Cases of PNET in 7 MM (2017-2028)

Figure 2: Prevalence of PNET in the United States (2017-2028)

Figure3: Functionality based prevalence of PNET in the United States (2017-2028)

Figure4: Symptom based Prevalence of Functional PNET in the United States (2017-2028)

Figure5: Stage-wise prevalence of PNET in the United States (2017-2028)

Figure6: Grade-wise prevalence of PNET in the United States (2017-2028)

Figure7: Gender-specific prevalence of PNET in the United States (2017-2028)

Figure 8: Prevalence of PNET in Germany (2017-2028)

Figure9: Functionality based prevalence of PNET in Germany (2017-2028)

Figure10: Symptom based Prevalence of Functional PNET in Germany (2017-2028)

Figure11: Stage-wise prevalence of PNET in Germany (2017-2028)

Figure12: Grade-wise prevalence of PNET in Germany (2017-2028)

Figure13: Gender-specific prevalence of PNET in Germany (2017-2028)

Figure 14: Prevalence of PNET in France (2017-2028)

Figure15: Functionality based prevalence of PNET in France (2017-2028)

Figure16: Symptom based Prevalence of Functional PNET in France (2017-2028)

Figure17: Stage-wise prevalence of PNET in France (2017-2028)

Figure18: Grade-wise prevalence of PNET in France (2017-2028)

Figure19: Gender-specific prevalence of PNET in France (2017-2028)

Figure 20: Prevalence of PNET in Italy (2017-2028)

Figure21: Functionality based prevalence of PNET in Italy (2017-2028)

Figure22: Symptom based Prevalence of Functional PNET in Italy (2017-2028)

Figure23: Stage-wise prevalence of PNET in Italy (2017-2028)

Figure24: Grade-wise prevalence of PNET in Italy (2017-2028)

Figure25: Gender-specific prevalence of PNET in Italy (2017-2028)

Figure 26: Prevalence of PNET in Spain (2017-2028)

Figure27: Functionality based prevalence of PNET in Spain (2017-2028)

Figure28: Symptom based Prevalence of Functional PNET in Spain (2017-2028)

Figure29: Stage-wise prevalence of PNET in Spain (2017-2028)

Figure30: Grade-wise prevalence of PNET in Spain (2017-2028)

Figure31: Gender-specific prevalence of PNET in Spain (2017-2028)

Figure 32: Prevalence of PNET in the UK (2017-2028)

Figure33: Functionality based prevalence of PNET in the UK (2017-2028)

Figure34: Symptom based Prevalence of Functional PNET in the UK (2017-2028)

Figure35: Stage-wise prevalence of PNET in the UK (2017-2028)

Figure36: Grade-wise prevalence of PNET in the UK (2017-2028)

Figure37: Gender-specific prevalence of PNET in the UK (2017-2028)

Figure 38: Prevalence of PNET in Japan (2017-2028)

Figure39: Functionality based prevalence of PNET in Japan (2017-2028)

Figure40: Symptom based Prevalence of Functional PNET in Japan (2017-2028)

Figure41: Stage-wise prevalence of PNET in Japan (2017-2028)

Figure42: Grade-wise prevalence of PNET in Japan (2017-2028)

Figure43: Gender-specific prevalence of PNET in Japan (2017-2028)

Figure 44: Treatment algorithm according to NCCN guidelines

Figure 45: Treatment algorithm according to NCCN guidelines

Figure 46: Treatment algorithm according to NCCN guidelines

Figure 47: Treatment algorithm according to NCCN guidelines

Figure 48: Treatment algorithm according to NCCN guidelines

Figure 49: Treatment algorithm according to NCCN guidelines

Figure 50: Treatment algorithm according to NCCN guidelines

Figure 51: Unmet Needs for Pancreatic Neuroendocrine Tumor (PNET)

Figure 52: Market Size of PNET in 7MM, USD Million (2017-2028)

Figure 53: Market Size of PNET by Therapies in 7MM, USD Million (2017-2028)

Figure 54: Market Size of PNET in the US, USD Millions (2017-2028)

Figure 55: PNET Market Size by Therapies in the US, USD Million (2017-2028)

Figure 56: Market Size of PNET in Germany, USD Millions (2017-2028)

Figure 57: PNET Market Size by therapies in Germany, USD Million (2017-2028)

Figure 58: Market Size of PNET in France, USD Millions (2017-2028)

Figure 59: PNET Market Size by therapies in France, USD Million (2017-2028)

Figure 60: Market Size of PNET in Italy, USD Millions (2017-2028)

Figure 61: PNET Market Size by therapies in Italy, USD Million (2017-2028)

Figure 62: Market Size of PNET in Spain, USD Millions (2017-2028)

Figure 63: PNET Market Size by therapies in Spain, USD Million (2017-2028)

Figure 64: Market Size of PNET in the UK, USD Millions (2017-2028)

Figure 65: PNET Market Size by therapies in the UK, USD Million (2017-2028)

Figure 66: Market Size of PNET in Japan, USD Millions (2017-2028)

Figure 67: PNET Market Size by therapies in Japan, USD Million (2017-2028)

Figure 68: Market Drivers for Pancreatic Neuroendocrine Tumor (PNET)

Figure 69: Market Barriers for Pancreatic Neuroendocrine Tumor (PNET)

  • Tags:
  • Pancreatic Neuroendocrine Tumors (P...
  • Pancreatic Neuroendocrine Tumors (P...
  • Pancreatic Neuroendocrine Tumors (P...
  • Pancreatic Neuroendocrine Tumors (P...
  • Pancreatic Neuroendocrine Tumors (P...
  • Pancreatic Neuroendocrine Tumors (P...
  • Pancreatic Neuroendocrine Tumors (P...
  • Pancreatic Neuroendocrine Tumors (P...
  • Pancreatic Neuroendocrine Tumors (P...
  • Pancreatic Neuroendocrine Tumors (P...
  • Pancreatic Neuroendocrine Tumors (P...
  • Pancreatic Neuroendocrine Tumors (P...
  • Pancreatic Neuroendocrine Tumors (P...
  • Pancreatic Neuroendocrine Tumors (P...
  • Pancreatic Neuroendocrine Tumors (P...
  • Pancreatic Neuroendocrine Tumors (...

Forward to Friend

Need A Quote